Related Experiment Video
Updated: May 6, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
Cardiac Manifestations of KCNK17 Mutations and/or Polymorphisms: A Systematic Review
Amir Askarinejad1, Mahshid Malakootian2, Dorsa Shekouh3
1Liverpool Center for Cardiovascular Sciences at University of Liverpool Liverpool John Moores University and Liverpool Heart & Chest Hospital Liverpool UK.
Background And Aims:
The KCNK17 gene encodes k2p17.1 channels (TASK-4 or TALK-2) with dominant expressions in the atria and the Purkinje fibers. Emerging studies have suggested possible associations between KCNK17 variants and cardiovascular as well as cerebrovascular diseases. This review aimed to systematically evaluate the evidence on KCNK17 mutations and/or polymorphisms in cardiovascular diseases (primary outcome) and cerebrovascular diseases (secondary outcome). Given the fragmented and limited evidence, a systematic review is warranted to summarize current knowledge and clarify potential clinical implications.
Methods:
PubMed, MEDLINE, Embase, Web of Science, and Scopus were searched for studies evaluating any cardiovascular or cerebrovascular diseases associated with KCNK17 published up to August 1, 2023. Inclusion criteria were original studies reporting KCNK17 mutations and/or polymorphisms in relation to cardiovascular diseases (primary outcome) or cerebrovascular diseases (secondary outcome). Exclusion criteria were studies evaluating pharmacological interventions on the K2P17.1 (TALK-2) channel, as well as reviews, editorials, and non-original articles.
Results:
Nine studies concerning KCNK17 were finally included in the systematic review. Six studies evaluated cardiovascular diseases, including atrial fibrillation, cancer-induced cardiac dysfunction, long QT syndrome, and progressive cardiac conduction defects, and 3 studies evaluated cerebrovascular diseases, including ischemic stroke and cerebral hemorrhage.
Conclusions:
Recent genetic discoveries in the aforementioned diseases warrant further research to develop innovative cardiovascular treatments based on KCNK17.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Related Concept Videos
Mitral Stenosis II: Clinical features and Diagnostic Tests
Heart Failure III: Clinical Manifestations
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy